James G. Marken
2016
In 2016, James G. Marken earned a total compensation of $642.3K as Senior Vice President, Operations and Product Development at ANI Pharmaceuticals, a 10% increase compared to previous year.
Compensation breakdown
| Bonus | $46,751 |
|---|---|
| Non-Equity Incentive Plan | $117,339 |
| Option Awards | $75,150 |
| Salary | $315,067 |
| Stock Awards | $76,106 |
| Other | $11,894 |
| Total | $642,307 |
Marken received $315.1K in salary, accounting for 49% of the total pay in 2016.
Marken also received $46.8K in bonus, $117.3K in non-equity incentive plan, $75.2K in option awards, $76.1K in stock awards and $11.9K in other compensation.
Rankings
In 2016, James G. Marken's compensation ranked 10,240th out of 14,075 executives tracked by ExecPay. In other words, Marken earned more than 27.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,240 out of 14,075 | 27th |
Division Manufacturing | 3,960 out of 5,489 | 28th |
Major group Chemicals And Allied Products | 1,396 out of 1,895 | 26th |
Industry group Drugs | 1,116 out of 1,538 | 27th |
Industry Pharmaceutical Preparations | 873 out of 1,176 | 26th |
Source: SEC filing on April 6, 2017.
Marken's colleagues
We found four more compensation records of executives who worked with James G. Marken at ANI Pharmaceuticals in 2016.
2016
Arthur Przybyl
ANI Pharmaceuticals
Chief Executive Officer
2016
Charlotte Arnold
ANI Pharmaceuticals
Chief Financial Officer
2016
Stephen Carey
ANI Pharmaceuticals
Chief Financial Officer
2016
Robert Schrepfer
ANI Pharmaceuticals
Senior Vice President, New Business Development and Specialty Sales
News
ANI Pharmaceuticals CEO Nikhil Lalwani's 2021 pay jumps 76% to $6.5M
March 25, 2022
ANI Pharmaceuticals CEO Nikhil Lalwani receives $3.7M in 2020
April 29, 2021
ANI Pharmaceuticals CEO Arthur Przybyl's 2019 pay jumps 39% to $5.8M
April 23, 2020
ANI Pharmaceuticals CEO Arthur Przybyl's 2018 pay rises 17% to $4.2M
April 4, 2019